BLANDIZZI, CORRADO Statistiche
BLANDIZZI, CORRADO
DIPARTIMENTO DI MEDICINA CLINICA E SPERIMENTALE
Serum triiodothyronine-to-thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients
In corso di stampa Bertani, L; Tricò, D; Pugliese, D; Privitera, G; Linsalata, G; Zanzi, F; Mumolo, Mg; Barberio, B; Monzani, F; Marchi, S; Guidi, L; Blandizzi, C; Armuzzi, A; Costa, F
Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy
2023-01-01 Convertino, I.; Cazzato, M.; Tillati, S.; Giometto, S.; Gini, R.; Valdiserra, G.; Cappello, E.; Ferraro, S.; Bonaso, M.; Bartolini, C.; Paoletti, O.; Lorenzoni, V.; Trieste, L.; Filippi, M.; Turchetti, G.; Cristofano, M.; Blandizzi, C.; Mosca, M.; Lucenteforte, E.; Tuccori, M.
Author Correction: Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology (npj Parkinson's Disease, (2022), 8, 1, (9), 10.1038/s41531-021-00263-x)
2023-01-01 Pellegrini, C.; D'Antongiovanni, V.; Miraglia, F.; Rota, L.; Benvenuti, L.; Di Salvo, C.; Testa, G.; Capsoni, S.; Carta, G.; Antonioli, L.; Cattaneo, A.; Blandizzi, C.; Colla, E.; Fornai, M.
Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis
2023-01-01 Convertino, I.; Lorenzoni, V.; Gini, R.; Turchetti, G.; Fini, E.; Giometto, S.; Bartolini, C.; Paoletti, O.; Ferraro, S.; Cappello, E.; Valdiserra, G.; Bonaso, M.; Blandizzi, C.; Tuccori, M.; Lucenteforte, E.
Role of cyclooxygenase pathways in bowel fibrotic remodelling in a murine model of experimental colitis
2023-01-01 Colucci, Rocchina; Fornai, Matteo; Antonioli, Luca; Segnani, Cristina; Ippolito, Chiara; Pellegrini, Carolina; Nericcio, Anna; Zizzo, Maria Grazia; Serio, Rosa; Blandizzi, Corrado; Bernardini, Nunzia
Exploring the relationship between utilization patterns of biologic disease-modifying anti-rheumatic drugs and disease activity in rheumatoid arthritis patients
2022-01-01 Convertino, Irma; Cazzato, Massimiliano; Tillati, Silvia; Giometto, Sabrina; Gini, Rosa; Valdiserra, Giulia; Cappello, Emiliano; Ferraro, Sara; Bonaso, Marco; Bartolini, Claudia C.; Paoletti, Olga; Lorenzoni, Valentina; Filippi, Matteo; Turchetti, Giuseppe; Cristofano, Michele; Blandizzi, Corrado; Mosca, Marta; Lucenteforte, Ersilia; Tuccori, Marco
Adenosine signaling in the tumor microenvironment
2021-01-01 Antonioli, L.; Fornai, M.; Pellegrini, C.; D'Antongiovanni, V.; Turiello, R.; Morello, S.; Hasko, G.; Blandizzi, C.
Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy)
2021-01-01 Bartolini, C; Ferraro, S; Convertino, I; Bertani, L; Giometto, S; Costa, F; Blandizzi, C; Lucenteforte, E; Gini, R; Tuccori, M
Analysis of fatal adverse drug events recorded in several Italian emergency departments (the MEREAFaPS study)
2021-01-01 Pagani, S.; Lombardi, N.; Crescioli, G.; Vighi, G. V.; Spada, G.; Romoli, I.; Andreetta, P.; Capuano, A.; Marrazzo, E.; Marra, A.; Leoni, O.; Vannacci, A.; Venegoni, M.; Vighi, G. D.; Bettoni, D.; Blandizzi, C.; Bonaiuti, R.; Borsi, V.; Cecchi, E.; Convertino, I.; Del Lungo, M.; Di Mauro, C.; Farina, G.; Ferraro, S.; Fucile, A.; Galfrascoli, E.; Geninatti, E.; Giovannetti, L.; Leonardi, L.; Liccardo, R.; Monina, G.; Mugelli, A.; Pagani, S.; Parrilli, M.; Rafaniello, C.; Rossi, F.; Rostan, S.; Ruocco, M.; Sironi, M.; Sportiello, L.; Tuccori, M.
Assessment of Healthcare Facilities Associated with JAKi Drugs Used in Rheumatoid Arthritis Patients in Tuscany, Italy: The LEONARDO
2021-01-01 Valdiserra, G.; Convertino, I.; Giometto, S.; Lorenzoni, V.; Gini, R.; Turchetti, G.; Fini, E.; Bartolini, C.; Paoletti, O.; Ferraro, S.; Cappello, E.; Blandizzi, C.; Lucenteforte, E.; Tuccori, M.
COMPOSTI INIBITORI DELL’INFLAMMASOMA NLRP3 E LORO USO
2021-01-01 Pellegrini, Carolina; Antonioli, Luca; Fornai, Matteo; Blandizzi, Corrado; Colucci, ROCCHINA LUCIA; Massimo, Bertinaria; Elisabetta, Marini; Valentina, Boscaro; Simone, Gastaldi; Mattia, Cocco
Diagnostic delay, effectiveness and safety outcomes in a real-world cohort of patients with Crohn's disease: Data from administrative databases in Tuscany, Italy
2021-01-01 Ferraro, S; Bartolini, C; Convertino, I; Bertani, L; Giometto, S; Cappello, E; Valdiserra, G; Tillati, S; Blandizzi, C; Lucenteforte, E; Costa, F; Gini, R; Tuccori, M
Direct health care costs among patients with rheumatoid arthritis before and after the initiation of treatment with JAKi in Tuscany: The LEONARDO study
2021-01-01 Lorenzoni, V; Tuccori, M; Gini, R; Fini, E; Giometto, S; Bartolini, C; Paoletti, O; Convertino, I; Ferraro, S; Cappello, E; Valdiserra, G; Blandizzi, C; Lucenteforte, E; Turchetti, G
Donepezil improves vascular function in a mouse model of Alzheimer's disease
2021-01-01 Pellegrini, Carolina; D'Antongiovanni, Vanessa; Fornai, Matteo; Duranti, Emiliano; Baldacci, Filippo; Bernardini, Nunzia; Taddei, Stefano; Virdis, Agostino; Blandizzi, Corrado; Masi, Stefano; Antonioli, Luca
Longitudinal adherence trajectories to biologic disease modifying anti-rheumatic drugs in Tuscany, Italy
2021-01-01 Giometto, S; Convertino, I; Tuccori, M; Gini, R; Cazzato, M; Valdiserra, G; Cappello, E; Ferraro, S; Tillati, S; Fornili, M; Bartolini, C; Paoletti, O; Turchetti, G; Trieste, L; Lorenzoni, V; Blandizzi, C; Mosca, M; Lucenteforte, E
Managing Obesity and Related Comorbidities: A Potential Pharmacological Target in the Adenosine System?
2021-01-01 D'Antongiovanni, V.; Fornai, M.; Pellegrini, C.; Blandizzi, C.; Antonioli, L.
NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implications
2021-01-01 Pellegrini, C.; Martelli, A.; Antonioli, L.; Fornai, M.; Blandizzi, C.; Calderone, V.
Olfactory and gustatory impairments in COVID-19 patients: Role in early diagnosis and interferences by concomitant drugs
2021-01-01 Ferraro, S.; Tuccori, M.; Convertino, I.; Valdiserra, G.; Cappello, E.; Maggi, F.; Blandizzi, C.; Focosi, D.
Oral sucrosomial iron is as effective as intravenous ferric carboxy‐maltose in treating anemia in patients with ulcerative colitis
2021-01-01 Bertani, L.; Trico, D.; Zanzi, F.; Svizzero, G. B.; Coppini, F.; de Bortoli, N.; Bellini, M.; Antonioli, L.; Blandizzi, C.; Marchi, S.
Preclinical development of fa5, a novel amp-activated protein kinase (Ampk) activator as an innovative drug for the management of bowel inflammation
2021-01-01 Antonioli, L.; Pellegrini, C.; Fornai, M.; Benvenuti, L.; D'Antongiovanni, V.; Colucci, R.; Bertani, L.; Di Salvo, C.; Semeghini, G.; Motta, C. L.; Giusti, L.; Zallocco, L.; Ronci, M.; Quattrini, L.; Angelucci, F.; Coviello, V.; Oh, W. -K.; Ha, Q. T. K.; Nemeth, Z. H.; Hasko, G.; Blandizzi, C.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Serum triiodothyronine-to-thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients | In corso di stampa | Bertani, L; Tricò, D; Pugliese, D; Privitera, G; Linsalata, G; Zanzi, F; Mumolo, Mg; Barberio, B; Monzani, F; Marchi, S; Guidi, L; Blandizzi, C; Armuzzi, A; Costa, F | |
| Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy | 1-gen-2023 | Convertino, I.; Cazzato, M.; Tillati, S.; Giometto, S.; Gini, R.; Valdiserra, G.; Cappello, E.; Ferraro, S.; Bonaso, M.; Bartolini, C.; Paoletti, O.; Lorenzoni, V.; Trieste, L.; Filippi, M.; Turchetti, G.; Cristofano, M.; Blandizzi, C.; Mosca, M.; Lucenteforte, E.; Tuccori, M. | |
| Author Correction: Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology (npj Parkinson's Disease, (2022), 8, 1, (9), 10.1038/s41531-021-00263-x) | 1-gen-2023 | Pellegrini, C.; D'Antongiovanni, V.; Miraglia, F.; Rota, L.; Benvenuti, L.; Di Salvo, C.; Testa, G.; Capsoni, S.; Carta, G.; Antonioli, L.; Cattaneo, A.; Blandizzi, C.; Colla, E.; Fornai, M. | |
| Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis | 1-gen-2023 | Convertino, I.; Lorenzoni, V.; Gini, R.; Turchetti, G.; Fini, E.; Giometto, S.; Bartolini, C.; Paoletti, O.; Ferraro, S.; Cappello, E.; Valdiserra, G.; Bonaso, M.; Blandizzi, C.; Tuccori, M.; Lucenteforte, E. | |
| Role of cyclooxygenase pathways in bowel fibrotic remodelling in a murine model of experimental colitis | 1-gen-2023 | Colucci, Rocchina; Fornai, Matteo; Antonioli, Luca; Segnani, Cristina; Ippolito, Chiara; Pellegrini, Carolina; Nericcio, Anna; Zizzo, Maria Grazia; Serio, Rosa; Blandizzi, Corrado; Bernardini, Nunzia | |
| Exploring the relationship between utilization patterns of biologic disease-modifying anti-rheumatic drugs and disease activity in rheumatoid arthritis patients | 1-gen-2022 | Convertino, Irma; Cazzato, Massimiliano; Tillati, Silvia; Giometto, Sabrina; Gini, Rosa; Valdiserra, Giulia; Cappello, Emiliano; Ferraro, Sara; Bonaso, Marco; Bartolini, Claudia C.; Paoletti, Olga; Lorenzoni, Valentina; Filippi, Matteo; Turchetti, Giuseppe; Cristofano, Michele; Blandizzi, Corrado; Mosca, Marta; Lucenteforte, Ersilia; Tuccori, Marco | |
| Adenosine signaling in the tumor microenvironment | 1-gen-2021 | Antonioli, L.; Fornai, M.; Pellegrini, C.; D'Antongiovanni, V.; Turiello, R.; Morello, S.; Hasko, G.; Blandizzi, C. | |
| Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy) | 1-gen-2021 | Bartolini, C; Ferraro, S; Convertino, I; Bertani, L; Giometto, S; Costa, F; Blandizzi, C; Lucenteforte, E; Gini, R; Tuccori, M | |
| Analysis of fatal adverse drug events recorded in several Italian emergency departments (the MEREAFaPS study) | 1-gen-2021 | Pagani, S.; Lombardi, N.; Crescioli, G.; Vighi, G. V.; Spada, G.; Romoli, I.; Andreetta, P.; Capuano, A.; Marrazzo, E.; Marra, A.; Leoni, O.; Vannacci, A.; Venegoni, M.; Vighi, G. D.; Bettoni, D.; Blandizzi, C.; Bonaiuti, R.; Borsi, V.; Cecchi, E.; Convertino, I.; Del Lungo, M.; Di Mauro, C.; Farina, G.; Ferraro, S.; Fucile, A.; Galfrascoli, E.; Geninatti, E.; Giovannetti, L.; Leonardi, L.; Liccardo, R.; Monina, G.; Mugelli, A.; Pagani, S.; Parrilli, M.; Rafaniello, C.; Rossi, F.; Rostan, S.; Ruocco, M.; Sironi, M.; Sportiello, L.; Tuccori, M. | |
| Assessment of Healthcare Facilities Associated with JAKi Drugs Used in Rheumatoid Arthritis Patients in Tuscany, Italy: The LEONARDO | 1-gen-2021 | Valdiserra, G.; Convertino, I.; Giometto, S.; Lorenzoni, V.; Gini, R.; Turchetti, G.; Fini, E.; Bartolini, C.; Paoletti, O.; Ferraro, S.; Cappello, E.; Blandizzi, C.; Lucenteforte, E.; Tuccori, M. | |
| COMPOSTI INIBITORI DELL’INFLAMMASOMA NLRP3 E LORO USO | 1-gen-2021 | Pellegrini, Carolina; Antonioli, Luca; Fornai, Matteo; Blandizzi, Corrado; Colucci, ROCCHINA LUCIA; Massimo, Bertinaria; Elisabetta, Marini; Valentina, Boscaro; Simone, Gastaldi; Mattia, Cocco | |
| Diagnostic delay, effectiveness and safety outcomes in a real-world cohort of patients with Crohn's disease: Data from administrative databases in Tuscany, Italy | 1-gen-2021 | Ferraro, S; Bartolini, C; Convertino, I; Bertani, L; Giometto, S; Cappello, E; Valdiserra, G; Tillati, S; Blandizzi, C; Lucenteforte, E; Costa, F; Gini, R; Tuccori, M | |
| Direct health care costs among patients with rheumatoid arthritis before and after the initiation of treatment with JAKi in Tuscany: The LEONARDO study | 1-gen-2021 | Lorenzoni, V; Tuccori, M; Gini, R; Fini, E; Giometto, S; Bartolini, C; Paoletti, O; Convertino, I; Ferraro, S; Cappello, E; Valdiserra, G; Blandizzi, C; Lucenteforte, E; Turchetti, G | |
| Donepezil improves vascular function in a mouse model of Alzheimer's disease | 1-gen-2021 | Pellegrini, Carolina; D'Antongiovanni, Vanessa; Fornai, Matteo; Duranti, Emiliano; Baldacci, Filippo; Bernardini, Nunzia; Taddei, Stefano; Virdis, Agostino; Blandizzi, Corrado; Masi, Stefano; Antonioli, Luca | |
| Longitudinal adherence trajectories to biologic disease modifying anti-rheumatic drugs in Tuscany, Italy | 1-gen-2021 | Giometto, S; Convertino, I; Tuccori, M; Gini, R; Cazzato, M; Valdiserra, G; Cappello, E; Ferraro, S; Tillati, S; Fornili, M; Bartolini, C; Paoletti, O; Turchetti, G; Trieste, L; Lorenzoni, V; Blandizzi, C; Mosca, M; Lucenteforte, E | |
| Managing Obesity and Related Comorbidities: A Potential Pharmacological Target in the Adenosine System? | 1-gen-2021 | D'Antongiovanni, V.; Fornai, M.; Pellegrini, C.; Blandizzi, C.; Antonioli, L. | |
| NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implications | 1-gen-2021 | Pellegrini, C.; Martelli, A.; Antonioli, L.; Fornai, M.; Blandizzi, C.; Calderone, V. | |
| Olfactory and gustatory impairments in COVID-19 patients: Role in early diagnosis and interferences by concomitant drugs | 1-gen-2021 | Ferraro, S.; Tuccori, M.; Convertino, I.; Valdiserra, G.; Cappello, E.; Maggi, F.; Blandizzi, C.; Focosi, D. | |
| Oral sucrosomial iron is as effective as intravenous ferric carboxy‐maltose in treating anemia in patients with ulcerative colitis | 1-gen-2021 | Bertani, L.; Trico, D.; Zanzi, F.; Svizzero, G. B.; Coppini, F.; de Bortoli, N.; Bellini, M.; Antonioli, L.; Blandizzi, C.; Marchi, S. | |
| Preclinical development of fa5, a novel amp-activated protein kinase (Ampk) activator as an innovative drug for the management of bowel inflammation | 1-gen-2021 | Antonioli, L.; Pellegrini, C.; Fornai, M.; Benvenuti, L.; D'Antongiovanni, V.; Colucci, R.; Bertani, L.; Di Salvo, C.; Semeghini, G.; Motta, C. L.; Giusti, L.; Zallocco, L.; Ronci, M.; Quattrini, L.; Angelucci, F.; Coviello, V.; Oh, W. -K.; Ha, Q. T. K.; Nemeth, Z. H.; Hasko, G.; Blandizzi, C. |